|
| US FDA committee recommends Allos' Folotyn to treat relapsed/refractory PTCL |
7 Sep 09, 03:51 |
|
| Allos Therapeutics, Inc announced that the US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with Folotyn (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). PTCL comprises a biologically diverse group of ... |
| more |
|
